Two-way sensitivity analysis on HCRU cost and transfusion avoidance probability with anti-C5 therapy (ie, SOC). Iptacopan was cost saving over SOC C5 inhibitors at high rates of transfusion avoidance in anti-C5–treated patients receiving SOC and low HCRU costs.